Login to Your Account


Recognizing that good science can be used for bad purposes or lead to harmful accidents, the National Science Advisory Board for Biosecurity (NSABB) debated the merits of an administration-imposed moratorium on government funding for so-called "gain-of-function" (GOF) research involving influenza, MERS and SARS viruses.

At the end of the day, does it really matter whether the Federal Circuit takes a fresh look at the construction of patent claims or defers to a lower court's interpretation of issues of fact?

LONDON – The Medicines and Healthcare products Regulatory Agency (MHRA) is promising to simplify the regulatory morass around regenerative medicines and cell therapies in the UK, with the setting up of a single point of access to advice for companies in the field.
More REGULATORY Headlines

Cast Your Vote

Has biotech’s bubble burst?: